This Drug Stock Could Keep Dropping

CELG's short interest shows there is no need to worry about a short squeeze

Mar 20, 2018 at 8:50 AM
facebook X logo linkedin


Shares of drugmaker Celgene Corporation (NASDAQ:CELG) have seriously struggled since October's record high above $147, last month breaching the $100 level -- a round-number mark that provided support throughout 2015 and 2016. Then, the Food and Drug Administration (FDA) rejected its multiple sclerosis drug, sending the stock spiraling to below $90. As such, CELG has trailed the S&P 500 Index (SPX) by roughly 20 percentage points over the past three months, and there's no reason to bet on a turnaround heading into its worst month of the year, with the equity losing almost 2% on average in April over the past three decades.

Monthly Chart of CELG Since Feb 17

It's not going to help if short sellers keep piling on, either. During the last two reporting periods alone, short interest increased 16.5%. And with just 2.1% of the float sold short, there's no need to worry about a short-squeeze situation.

Meanwhile, Celgene has received a number of bearish analyst notes in recent months, but the majority of those in coverage still have "strong buy" ratings in place. This leaves the stock at risk for additional downgrades.

CELG has been a good target over the past year for options traders, too, based on its Schaeffer's Volatility Scorecard (SVS) of 81 -- indicating a tendency to surpass volatility expectations. Lastly, our recommended put has a leverage ratio of negative 6.3, and will hit its profit target on a 13.3% decline in the underlying shares.

Subscribers to Schaeffer's Weekend Trader Series options recommendation service received this CELG commentary on Sunday night, along with a detailed options trade recommendation -- including complete entry and exit parameters. Learn more about why Weekend Trader is one of our most popular options trading services.
 

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls

 
 
 


 
 

Rainmaker Ads CGI